Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis-Reference-Cited by-同舟云学术

Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis

Published:2017-02 Issue: Volume:31 Page:114-120
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Bonotto Marta,Gerratana Lorenzo,Di Maio Massimo,De Angelis Carmine,Cinausero Marika,Moroso Stefano,Milano Monica,Stanzione Brigida,Gargiulo Piera,Iacono Donatella,Minisini Alessandro Marco,Mansutti Mauro,Fasola Gianpiero,De Placido Sabino,Arpino Grazia,Puglisi Fabio

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference23 articles.

1. Cancer statistics;Siegel;CA Cancer J Clin,2016

2. Breast cancer metastasis: challenges and opportunities;Lu;Cancer Res,2009

3. Measures of outcome in metastatic breast cancer: insights from a real-world scenario;Bonotto;Oncol,2014

4. How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials;Kiely;J Clin Oncol Off J Am Soc Clin Oncol,2011

5. Features of aggressive breast cancer;Arpino;Breast Edinb Scotl,2015

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring pharmacokinetic variability of palbociclib in HR+/HER2- metastatic breast cancer: a focus on age, renal function, and drug–gene interactions;Frontiers in Pharmacology;2024-09-06

2. The treatment pattern of advanced HR-positive and HER2-negative breast cancer in central southern China: a hospital-based cross-sectional study;BMC Cancer;2024-07-30

3. Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, advanced or metastatic breast cancer;Cancer Chemotherapy and Pharmacology;2024-06-27

4. Capecitabine monotherapy as first-line treatment in advanced HER2-normal breast cancer – a nationwide, retrospective study;Acta Oncologica;2024-06-23

5. Identifying drivers of first-line HR+/HER2− metastatic breast cancer treatment choices;Future Oncology;2024-06-04